Company intelligence / Profile preview
Synovo
Tübingen, Baden-Württemberg, Germanysynovo.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Synovo’s lead candidate SYD003 has received Orphan Drug designation from both the EMA and FDA for pancreatic cancer. The company also develops other small molecule therapeutics targeting inflammation and immune processes. Some programs are in preclinical or early clinical stages.
- Therapeutic areas
- OncologyPulmonologyImmunology
- Modalities
- Small moleculeProteinNucleic acid drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with public sector laboratories/universities worldwidePharma clientsResearch partners globallyTechnology Park Tübingen Reutlingen Consortium
Beyond the preview
Go deeper on Synovo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synovo.